What do you do when a company has “more debt than assets?” Maxim’s Jason Kolbert just lost patience with MNKD.
MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes, today announced the appointment of …
As MannKind spends precious cash, it moves closer to the next capital raise (a.k.
One of the world’s top fund managers is backing volatile healthcare stocks VRX and MNKD.
H.C.
Jason Kolbert recently downgraded MNKD on cash flow concerns; after this Q3 print, looks like he was right.
Both TRXC and MNKD offer potentially big rewards, but at what cost?
MannKind’s capital raise is not enough, says Jason Kolbert.
Oren Livnat believes MNKD’s revised debt arrangements will be advantageous to the Afrezza launch.
MannKind Corporation (NASDAQ:MNKD) and BIOMM announced the submission of a registration dossier to ANVISA, seeking the approval of Afrezza® (insulin human) inhalation powder …
